a public good project by the
Synthesis
Company
of California

© 2026

Mark G. Saulnier | doi.page

0 works0 citations0 h-index

Mark G. Saulnier

Bristol-Myers Squibb (United States)(US)

Publications by Year

Research Areas

Cancer therapeutics and mechanisms, Bioactive Compounds and Antitumor Agents, Growth Hormone and Insulin-like Growth Factors, Chemical synthesis and alkaloids, Metabolism, Diabetes, and Cancer

Most-Cited Works

→ Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.(1988)235 cited
→ Tumor Development by Transgenic Expression of a Constitutively Active Insulin-Like Growth Factor I Receptor(2005)203 cited
→ In vitro and In vivo Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417(2006)177 cited
→ Generation and reactions of 3-lithio-1-(phenylsulfonyl)indole(1982)170 cited
→ Synthesis and Diels-Alder reactions of 1,3-dimethyl-4-(phenylsulfonyl)-4H-furo[3,4-b]indole. A new annulation strategy for the construction of ellipticine and isoellipticine(1984)146 cited
→ Regioselective ortho lithiation of halopyridines(1980)142 cited

→ Discovery of a 1H-Benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) Inhibitor of Insulin-like Growth Factor I Receptor Kinase with in Vivo Antitumor Activity(2005)

134 cited

→ Quantitation of the Interaction of the Immunosuppressant Deoxyspergualin and Analogs with Hsc70 and Hsp90(1994)116 cited

→ An unusual oxidative cyclization. A synthesis and absolute stereochemical assignment of (-)-rocaglamide(1990)103 cited

→ Discovery of a 2,4-Disubstituted Pyrrolo[1,2-f][1,2,4]triazine Inhibitor (BMS-754807) of Insulin-like Growth Factor Receptor (IGF-1R) Kinase in Clinical Development(2009)94 cited